Northern Trust Corp 9 Meters Biopharma, Inc. Transaction History

Northern Trust Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.21 - $0.32 $2,109 - $3,214	-10,045 Reduced 2.23%	440,081 $94,000
Q2 2022 Aug 12, 2022	SELL	$0.26 - $0.64 $417,930 - $1.03 Million	-1,607,426 Reduced 78.12%	450,126 $117,000
Q1 2022 May 13, 2022	SELL	$0.52 - $1.0 $41,063 - $78,968	-78,968 Reduced 3.7%	2,057,552 $1.23 Million
Q4 2021 Feb 08, 2022	BUY	$0.85 - $1.33 $36,863 - $57,680	43,369 Added 2.07%	2,136,520 $2.09 Million
Q3 2021 Nov 15, 2021	BUY	$1.03 - $1.41 $1.4 Million - $1.92 Million	1,360,109 Added 185.54%	2,093,151 $2.72 Million
Q2 2021 Aug 13, 2021	BUY	$1.04 - $1.5 $428,788 - $618,445	412,297 Added 128.54%	733,042 $806,000
Q1 2021 May 12, 2021	BUY	$0.84 - $2.16 $90,762 - $233,388	108,050 Added 50.8%	320,745 $375,000
Q4 2020 Feb 11, 2021	BUY	$0.65 - $1.11 $59,419 - $101,469	91,414 Added 75.37%	212,695 $183,000
Q3 2020 Nov 16, 2020	BUY	$0.48 - $0.84 $38,419 - $67,234	80,041 Added 194.09%	121,281 $99,000
Q2 2020 Aug 14, 2020	BUY	$0.43 - $0.74 $17,733 - $30,517	41,240 New	41,240 $24,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.